Madrigal Pharmaceuticals has significantly bolstered its pipeline for metabolic dysfunction-associated steatohepatitis (MASH) by acquiring the global rights to Arrowhead Pharmaceuticals’…
Read More

Madrigal Pharmaceuticals has significantly bolstered its pipeline for metabolic dysfunction-associated steatohepatitis (MASH) by acquiring the global rights to Arrowhead Pharmaceuticals’…
Read More